Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvanted coronavirus vaccine - Dynavax Technologies/Medicago

Next Previous
Drug Profile

Adjuvanted coronavirus vaccine - Dynavax Technologies/Medicago

Alternative Names: Adjuvanted coronavirus recombinant vaccine - Dynavax Technologies/Medicago; Coronavirus-Like Particle COVID-19 Vaccine adjuvanted; CoVLP vaccine; Recombinant Coronavirus Virus-Like Particle vaccine - Dynavax Technologies/Medicago

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dynavax Technologies; Medicago
  • Developer Medicago
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 10 Feb 2026 Dynavax Technologies has been acquired by Sanofi
  • 28 Aug 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Canada (IM)
  • 22 Apr 2022 Medicago completes a phase I trial in COVID-2019 infection (Prevention) in Canada (NCT04450004)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top